2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Bioinformatics, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Monoclonal Antibody Therapy, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, ALL, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Disparities Research, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

5089 Loss of B-cell aplasia and relapse in a real-world multicenter rocca cohort

Lacey Williams, MD, Amy Zhang, MPH2, Partow Kebriaei, MD3, LaQuisa Hill, MD4, Nitin Jain, MD5, Stephanie B Tsai, MD6, Aaron C. Logan, MD, PhD, MPhil7, Jae H Park, MD8, Gregory W Roloff, MD9, Matthew L. Ulrickson, MD10, Veronika Bachanova, MD, PhD11, Sean I. Tracy, MD, PhD12, Sumithira Vasu, MBBS., MD13, Rawan Faramand, MD14, Yannis K. Valtis I, MD15, Elias Jabbour, MD16, Jumana Hoque, MBBS17, Tamer Othman, MD18, Timothy Edward O'Connor, MD19, Karamjeet Singh Sandhu, MD20, Virginia Tan, MD21, Jiasheng Wang, MD22, Hrishikesh Srinagesh, MD, MSCR23, Caspian Oliai, MD24, Georgia Lill, MD25, Meera Khosla, MD26, Kaitlyn Cecilia Dykes, MD27, Ken Byrd, DO28, Matthew P Connor, MD29, Jozal Moore, MD30, Kristen O'Dwyer, MD31, Noelle Frey, MD, MSCE32, Katherine Sutherland, PA33, Ibrahim Aldoss, MD34, Bijal Shah, MD, MS35, Lori Muffly, MD36, Jessica Leonard I, M.D.37
1 UNC School of Medicine, Alexandria, Virginia, United States
2 Stanford University School of Medicine, Palo Alto, California, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 Baylor College of Medicine, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 Loyola University Medical Center, Maywood, Illinois, United States
7 University of California San Francisco School of Medicine, San Francisco, California, United States
8 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
9 University of Chicago, Chicago, Illinois, United States
10 Banner MD Anderson Cancer Center, Phoenix, Arizona, United States
11 University of Minnesota, Minneapolis, Minnesota, United States
12 University of Minnesota, Minneapolis, Minnesota, United States
13 The Ohio State College of Medicine, Columbus, Ohio, United States
14 Moffitt Cancer Center, Tampa, Florida, United States
15 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 Banner MD Anderson Cancer Center, Phoenix, Arizona, United States
18 City of Hope, Duarte, California, United States
19 Loyola University Medical Center, Maywood, Illinois, United States
20 City of Hope, Duarte, California, United States
21 Oregon Health & Science University, Portland, Oregon, United States
22 The Ohio State College of Medicine, Columbus, Ohio, United States
23 Stanford University School of Medicine, Palo Alto, California, United States
24 UCLA School of Medicine, Los Angeles, California, United States
25 UCLA School of Medicine, Los Angeles, California, United States
26 Baylor College of Medicine, Houston, Texas, United States
27 University of California San Diego School of Medicine, La Jolla, California, United States
28 University of Kansas Medical Center, Kansas City, Kansas, United States
29 University of Pennsylvania, Philadelphia, Pennsylvania, United States
30 University of Rochester School of Medicine and Dentistry, Rochester, New York, United States
31 University of Rochester School of Medicine and Dentistry, Rochester, New York, United States
32 University of Pennsylvania, Philadelphia, Pennsylvania, United States
33 Stanford University School of Medicine, Palo Alto, California, United States
34 City of Hope, Duarte, California, United States
35 Moffitt Cancer Center, Tampa, Florida, United States
36 Stanford University School of Medicine, Palo Alto, California, United States
37 Oregon Health & Science University, Portland, Oregon, United States

Introduction: Loss of B cell aplasia (LOBA) or B cell recovery is considered a surrogate marker for loss of functional CAR-T cells in patients with B-cell acute lymphoblastic leukemia (B-ALL). Prior studies have shown that LOBA within 1 year of CD-19 directed CAR-T cell therapy has been associated with an increased risk of relapse in patients with B-ALL (Gardner, Blood, 2017; Pulsipher, Blood Cancer Discov, 2022). In the FELIX study, most relapses occurring in the setting of ongoing CAR-T persistence were CD19-negative, consistent with antigen escape (Roddie, NEJM, 2024). Importantly, relapses following LOBA have not been associated with an increased risk of CD19-negative relapse. We evaluated the relationship between LOBA and relapse in a real-world cohort of patients with relapsed/refractory (R/R) B-ALL treated with obe-cel.

Methods: Patient characteristics and outcomes were obtained from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA) database of which 18 U.S. centers contributed to this analysis. Patients who received obe-cel as part of standard of care and had B-cell aplasia assessments were included. LOBA was defined as return of detectible CD19+ cells in the absence of disease progression as reported by clinical sites; patients who had concurrent relapse and B cell recovery were not considered to have antecedent LOBA. The primary objective was to evaluate the association between LOBA and subsequent relapse. Secondary objectives included the incidence and timing of loss of B-cell aplasia, incidence of CD19+ vs CD19- relapse, and event free survival (EFS) and overall survival (OS). Landmark analysis at day +125 was used to compare survival probabilities between patients that did or did not experience LOBA.

Results: Among 158 patients with R/R B-ALL infused with obe-cel and reported in the ROCCA registry, 137 had a disease assessment at day 28, of whom 134 achieved complete remission (CR). Eighty-four patients had evaluable post-infusion B-cell quantification assessments and comprised the primary analysis cohort. Within this cohort, 42% were female, the median age was 49 years, and 25% had Philadelphia chromosome-positive disease. Prior therapies included blinatumomab (58%), inotuzumab ozogamicin (29%), allogeneic hematopoietic stem cell transplantation (23%), and prior CD19 CAR T-cell therapy (6%).

Twelve of 84 patients (14%) experienced LOBA, of whom 25% subsequently relapsed. The median time from infusion to loss of B cell aplasia was 125 days (IQR 98–153), with 92% of these patients experiencing B-cell recovery between 3 and 6 months. Landmark analysis demonstrated that among patients who were event-free at day +125, there was no significant difference in EFS between those who maintained B-cell aplasia compared with those who had LOBA (EFS 83% vs. 57%, p=0.47); OS 86% vs 86%, p=0.87).

Seventeen patients (20%) experienced relapse at a median of 128 days after infusion (IQR 114–199). Three of the 12 patients with loss of B-cell aplasia experienced relapse, none of which were associated with loss of CD19 expression. Among the remaining 14 relapses, 7/12 (58%)

were CD19-negative, and none of these patients had preceding LOBA. Two patients did not have data on CD19 expression after relapse.

Conclusions: In this real-world analysis, we did not observe a statistically significant association between LOBA and subsequent relapse, EFS, or OS. Consistent with prior studies, relapses following LOBA retained CD19 expression, whereas relapses occurring in the setting of ongoing B-cell aplasia were more frequently CD19-negative, supporting distinct mechanisms of relapse related to loss of CAR T-cell persistence versus antigen escape. The relatively small sample size and limited duration of follow-up preclude definitive conclusions regarding long-term outcomes. In addition, variability in the timing of B-cell aplasia assessments within this real-world registry may have resulted in under-detection of B-cell recovery preceding relapse, particularly among patients in whom relapse and B-cell recovery were documented simultaneously. Assessment of B-cell aplasia should be interpreted alongside other post-CAR T-cell disease monitoring tools, including next-generation sequencing (NGS)-based measurable residual disease (MRD) assessment and CAR-T persistence assays. The optimal management of patients who experience B-cell recovery after CAR-T therapy remains unknown and warrants prospective investigation.

Lacey Williams, MD: Geron - Honoraria; Onviv - Honoraria; binaytara - Honoraria; Autolus - Honoraria